Advertisement

a method validation question-urgent please

Discussions about HPLC, CE, TLC, SFC, and other "liquid phase" separation techniques.

9 posts Page 1 of 1
Hi, we have been suffering from resolution failure issues on a validated assay method with different lots of waters columns (same type). USP criteria is NLT 3.0 and we have had 2.8. Waters did not think it was a column issue.

We ran the same std on a USP equivalent column (phenomenex instead of waters) and found the resolution was 5.0. what parameters do we need to validate to qualify the equivalent column can be used for this method? Note this is an assay method for DP and API.

Thanks.
It depends on how you described this in your SOPs, but I think you can use whatever column that meets the specified dimensions and stationary phase, as long as you meet your system suitability limits.

So you have to meet the 3.0 resolution in this case I think.

Ace
If you specified in your SOP that "equivalent column" can be used also, at that case its acceptable without re-validation just so you demonstrate that you meet system suitability.
And the USP typically details simply "L1" or similar terminology and suppliers may each have a dozen L1 phases. My guess, and just a guess, is that you won't have to do much, or maybe even anything more than just document your change.

My guess (again, a guess) is that at most you'd need to document equivalent results of maybe three samples run on each column.
You can demonstrate the column equivalency. Run the analysis on the both column ans shows that there is not much diffence in the results.
Together we can...........
Hi: I thought that I would give you some useful information, which you can use now or when working on future USP methods.

USP has loosened method parameters quite a bit, giving plenty of room to change columns, mobile phase, etc. See the chromatography section in the USP for the allowable changes, etc. There is a way to eliminate or reduce the number of instances where one does not meet USP requirements.

Always include mobile phase modification and/or different vendor/brand of column in the alternate chromatography section of the validation. If only one brand/vendor's column is validated and written into the method, you are typically bound to use that column; however, by validating a second vendor column of the same type, you give yourself leeway, just in case the primary vendor is out of stock, having QA issues, etc. Also include modification of the mobile phase for a different brand of column, or even the same brand, but a different lot. Mobile phase modification is typically not an issue within one brand and one packing lot; however, if working with ionic compounds using a column made with older type A silica gel, difference in residual silanol sites from one batch of silica get to another can affect chromatographic separation. If possible, it is always better to use newer technology columns, those made with type B silica gel.

Check the USP website to determine which type and brand of column was used to establish the method. USP use to publish a book titled; "Columns Used in USP and NF Methods". They stopped printing this book several years ago, but it is now an online program at USP without any cost. In this program one can look up the monograph of interest, which will list the brand name of the column used for the method, whether it is the assay, purity, etc. As a part of this program, that was typically in the back section of the former book, is a list of all manufacturing qualifying columns, L1 and L7 being a very long list. Keep in mind that the description that USP gives in the monograph is general, not specific to differences in carbon load, type of endcapping bonding chemistry, etc. This leads us to the next program on USP's website.

USP also has a column comparison program that is used to determine the difference in the same type of column from one brand to another, such as C8, C18. It can be quite useful in determining which brand of column should work similarly to one you may already have in house. For example, there is a huge list of C18 columns that quality as L1; however, not all C18 columns perform the same. It has to do with differences in the type of silica gel, A or B, bonding chemistry, endcapped or not endcapped, type of endcapping, carbon load, surface area, ligand density, etc. A C18 phase is not going to change, but differences as mentioned above can create differences in performance. Be proactive and check the USP monograph column used for the method, and if you do not wish to use this column, check to see which column qualifies from another vendor and do the column comparison program before starting a new method.

Both of these programs are free, but you must register to use them.

Regards,
Linda
My supervisor does not agree that USP <621> changes can simply be utilized without validation studies, even though that is what is stated there. He feels that any changes must be validated or at least verified. I responded that if such studies were mandated, that it would state that ANY changes must be validated or at least verified.

For user-developed and user-validated methods under cGMP, FDA ORA-LAB.5.4.5 uses very similar limits as USP <621> for parameters (in its Attachment A, Modification Criteria), and states that those changes (temperature, column length, column diameter, etc.) do not require re-validation. Supervisor disagrees there, too.
Both of these programs are free, but you must register to use them.
For using the column equivalency databases provided by usp.org, there is no registration required. But I hope there are not columns with historical 'type-A' silica gel listed :twisted: .
I think Tom can us tell many details about this database ;-)

Nevertheless the approach from Consumer Products Guy seems to be correct for me.
My supervisor does not agree that USP <621> changes can simply be utilized without validation studies, even though that is what is stated there. He feels that any changes must be validated or at least verified. I responded that if such studies were mandated, that it would state that ANY changes must be validated or at least verified.

For user-developed and user-validated methods under cGMP, FDA ORA-LAB.5.4.5 uses very similar limits as USP <621> for parameters (in its Attachment A, Modification Criteria), and states that those changes (temperature, column length, column diameter, etc.) do not require re-validation. Supervisor disagrees there, too.
This is were the so-called "design space" comes into play.
If there was a robustness test performed (or as per today standards: QbD) with for example a temperature of 25°C and 35°C where the method states 30C, and you didn't find any changes in method performance, you can adapt your method within these temperature ranges without method re-validation.

Otherwise: if you met your system suitability criteria, then you should be safe, otherwise the criteria aren't strict enough.


Ace
9 posts Page 1 of 1

Who is online

In total there are 18 users online :: 2 registered, 0 hidden and 16 guests (based on users active over the past 5 minutes)
Most users ever online was 4374 on Fri Oct 03, 2025 12:41 am

Users browsing this forum: Bing [Bot], Google Adsense [Bot] and 16 guests

Latest Blog Posts from Separation Science

Separation Science offers free learning from the experts covering methods, applications, webinars, eSeminars, videos, tutorials for users of liquid chromatography, gas chromatography, mass spectrometry, sample preparation and related analytical techniques.

Subscribe to our eNewsletter with daily, weekly or monthly updates: Food & Beverage, Environmental, (Bio)Pharmaceutical, Bioclinical, Liquid Chromatography, Gas Chromatography and Mass Spectrometry.

Liquid Chromatography

Gas Chromatography

Mass Spectrometry